Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04839341
Other study ID # APL-106-01
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date February 24, 2021
Est. completion date February 28, 2023

Study information

Verified date September 2021
Source Apollomics Inc.
Contact Zhejiang CrownMab Ltd.
Phone 0571-83521933
Email ClinicalTrialsChina@apollomicsinc.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will evaluate the safety and tolerability of uproleselan(GMI-1271), a specific E-selectin antagonist, and characterize the pharmacokinetic (PK) profile of uproleselan, in combination with chemotherapy to treat Chinese relapsed/refractory AML patients.


Description:

This study is a multicenter open-labelled study conducted in subjects with relapsed or refractory AML in China. The study includes the following phases: screening phase, induction phase, consolidation phase baseline, consolidation phase and follow-up period. Screening phase: This study will enroll 12 subjects, who are 18 to 60 years (inclusive) at the time of signing the Informed Consent Form (ICF), and with the diagnosis as relapsed or refractory AML. Screening is conducted 21 days to 2 days before administration, and signed ICF by the subject must be obtained before screening. Baseline period: The baseline period is 1 day before study drug administration. Induction treatment: During the induction phase, subjects will receive 8 consecutive days of uproleselan treatment and 5 consecutive days of MEC (mitoxantrone, etoposide, and cytarabine combined regimen) chemotherapy. Consolidation baseline: The baseline of the consolidation phase is 1 day before the treatment administration of the consolidation phase. Consolidation treatment: Subjects who met the criteria for consolidation treatment started the consolidation period at the 29th day of the previous treatment cycle at the earliest and the 65th day at the latest. Follow-up period: Each subject should complete the following follow-up stage: (1) Response evaluation to determine remission to the induction treatment (induction period); (2) EOT assessment after completing the last consolidation treatment cycle; (3) Death. Survival and long-term follow-up, including initiation of new anti-leukemia treatment (within 6 months after the last uproleselan/placebo administration), recurrence, HSCT and survival events, monthly (±14 days) for 2 years after the end of treatment, and afterwards quarterly (±14 days). The longest survival follow-up time is 3 years (calculated from the start of treatment).


Recruitment information / eligibility

Status Recruiting
Enrollment 12
Est. completion date February 28, 2023
Est. primary completion date December 31, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Key Criteria: 1. =18 years and =60 years in age 2. AML (including secondary AML) diagnosed as per WHO standards (2008). 3. For refractory AML, only cytarabine/daunorubicin(or Idarubicin) as can be applied repeatedly(maximal twice) as induction, no other chemotherapy are allowed to be applied Venatoclax /hypomethylation drug [HMA] can be used before and after chemotherapy. 1. For relapse AML, it must be the first or second relapse, and remain untreated. 2. Certain regimens (Venatoclax/HMA, Venetoclax/LDAC, HMA single agent) and FLT3 inhibitors, tyrosine kinase inhibitors, IDH1/IDH2 inhibitors or similar targeted inhibitors used alone are not considered cytotoxic chemotherapy are allowed. 4. ECOG performance status score is 0 to 2. 5. Stable hemodynamics and good organ function and good organ function. Exclusion key Criteria: 1. Patients with acute promyelocytic leukemia, acute leukemia of ambiguous lineage (biphenotypic leukemia), chronic myeloid leukemia with myeloid blast crisis, or secondary refractory AML. 2. Active signs or symptoms of CNS involvement by malignancy. 3. Stem cell transplantation =4 months prior to dosing. 4. Any immunotherapy or radiotherapy therapy within 28 days of dosing; any other experimental therapy or chemotherapy within 14 days of dosing. 5. Prior use of G-CSF, CM-CSF or plerixafor within 7 days of dosing. 6. Inadequate organ function. 7. Abnormal liver function. 8. Known active infection with hepatitis A, B, or C, or human immunodeficiency virus. 9. Moderate kidney dysfunction (glomerular filtration rate <45 mL/min). 10. Uncontrolled acute life-threatening bacterial, viral, or fungal infection. 11. Clinically significant cardiovascular disease. 12. Major surgery within 4 weeks of dosing.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Uproleselan
A rationally designed E-selectin antagonist used to inhibit binding of cells to E-selectin

Locations

Country Name City State
China The First Affiliated Hospital of Zhejiang University Hangzhou
China Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Tianjin Tianjin

Sponsors (2)

Lead Sponsor Collaborator
Apollomics Inc. Zhejiang CrownMab Biotech Co. Ltd

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Peak plasma concentration (Tmax) To assess the pharmacokinetic profile in patients with relapsed/refractory AML. 14 days
Primary Peak plasma concentration (Cmax) To assess the pharmacokinetic profile in patients with relapsed/refractory AML. 14 days
Primary Area under the plasma concentration-time curve from time zero to 12 hours (AUC0-12) To assess the pharmacokinetic profile in patients with relapsed/refractory AML. 14 days
Primary The area under the plasma concentration-time curve (AUC0-t) from time zero to the last measurable time point To assess the pharmacokinetic profile in patients with relapsed/refractory AML. 14 days
Primary The Incidence of Adverse Events Number of participants with an AE. Up to 10 months
Primary The tolerance of participants with relapsed/refractory AML. Number of participants could tolerate the Uproleselan combined with chemotherapy. Up to 10 months
Secondary OS Defined as the period from when the subject receives the first dose of the study drug to death from any cause; Up to 3 years
Secondary Remission rate (rate of CR, CR/CRi and CR/CRh) Defined as the rate of subjects who reach CR, CR/CRi and CR/CRh; Up to 60 days
Secondary CTCAE grade 3 and 4 oral mucositis The incidence of CTCAE grade 3 and 4 oral mucositis during the treatment duration. Up to 254 days
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04623944 - NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS Phase 1
Completed NCT01258816 - The Pharmacokinetics and Cardiac Properties of Elacytarabine (CP-4055) Phase 1
Terminated NCT02520427 - A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies Phase 1
Recruiting NCT05054543 - Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML Phase 3
Not yet recruiting NCT05805072 - Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) Patients N/A
Completed NCT01319864 - POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients Phase 1
Recruiting NCT05428969 - A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies (BEXMAB) Phase 1/Phase 2
Recruiting NCT03631576 - CD123/CLL1 CAR-T Cells for R/R AML (STPHI_0001) Phase 2/Phase 3